



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** September 7, 2007

**To:** Primary Clinical Research Associates

**From:** Janis Wobschall  
Protocol Development Coordinator

**Re:** N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on February 9, 2007.

If you have any questions, please feel free to contact me.

Enclosure